Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07430267

Dilation Optimisation for Uniform Bioprosthetic Leaflet Expansion

Dilation Optimisation for Uniform Bioprosthetic Leaflet Expansion: The ACE-DOUBLE Trial

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
250 (estimated)
Sponsor
The Alfred · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal of this clinical trial is to discover if routine 'double tap' balloon post-dilation improves valve expansion and clinical outcomes in adults undergoing Transcatheter Aortic Valve Implantation (TAVI) with the SAPIEN balloon-expandable TAVI prosthesis. The primary hypothesis is that routine 'double tap' balloon post-dilation improves TAVI valve expansion. The secondary hypothesis is that routine 'double tap' balloon post-dilation improves TAVI valve haemodynamic performance. Participants will be randomised to balloon-expandable TAVI either with or without routine 'double tap' balloon post-dilation.

Detailed description

The ACE-DOUBLE trial will be a multicentre, registry nested, block randomized, open label clinical trial comparing routine versus discretionary balloon post-dilation strategies following TAVI using the SAPIEN 3 balloon-expandable THV for severe aortic stenosis (AS). Patients with severe symptomatic aortic valve disease that are accepted for TAVI using a balloon-expandable THV. Currently, the only balloon-expandable THV in routine clinical practice in Australia are the Sapien 3 Ultra and Sapien 3 Ultra Resilia (Edwards Lifesciences, Irvine CA, USA). Patients will be recruited from three TAVI centres participating in the ACE registry: The Alfred Hospital, Cabrini Hospital and Epworth Hospital are all located in Melbourne, Australia. Specific sub-groups may benefit more from balloon post-dilation (BPD), and hence exploratory analyses will be performed to examine the effect of BPD on primary endpoints in the following subgroups: * Male vs Female * Pre-dilation vs no pre-dilation * Tricuspid vs bicuspid aortic valve * Very severe AS (mean pressure gradient \> 50mmHg) * Very aortic valve high calcium score (\>3000 in males, \>1900 in females)

Conditions

Interventions

TypeNameDescription
OTHER'Double tap' balloon post-dilationRoutine second inflation of the valve delivery balloon ('double-tap') BPD following balloon-expandable valve TAVI

Timeline

Start date
2026-04-01
Primary completion
2028-04-01
Completion
2029-04-01
First posted
2026-02-24
Last updated
2026-02-24

Locations

3 sites across 1 country: Australia

Source: ClinicalTrials.gov record NCT07430267. Inclusion in this directory is not an endorsement.